BUSINESS

Generic Makers Positive on New AG Pricing, Cite Gains in Productivity and Predictability

By Tatsuya Otsuka January 8, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Generic makers in Japan have largely welcomed the new pricing rules for authorized generics (AGs) included in the finalized outline of the FY2026 drug pricing reform, saying the changes could improve production efficiency and business predictability, according to reactions from…

To read the full story

Pharma Leaders Press for Drug Pricing Overhaul at New Year’s Confab
January 8, 2026

BUSINESS

FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
Biomedix Takes Over Originator Data as Generics Face Supply, Information Challenge
February 13, 2026
Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
Nxera Gets US$1.8 Million Early-Stage Milestone from Centessa
February 13, 2026
Nxera Licenses GPCR Program to European VC-Backed Startup
February 13, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…